The 5th ADC Analytical Development Summit is the only dedicated platform for tackling the unique analytical complexities of ADC development, bringing together technical leaders to ensure a high-quality, regulatory-compliant ADC product.
The ADC landscape is undergoing a rapid transformation with novel modalities like bispecifics, dual payload conjugates, and novel conjugates all push the boundaries of innovation, whilst more traditional ADCs are progressing their way through the pipelines - analytical teams are facing greater challenges in ensuring product quality and regulatory compliance than ever. The 5th ADC Analytical Development Summit is your essential, technical, forum to unite with your analytical development peers and senior decision makers to deep dive and combat challenges spanning early-stage to later-stage analytical development and take away actionable insights for your ADC programs.
What to Expect at the 5th ADC Analytical Development Summit?
The 5th ADC Analytical Development Summit is designed to equip you and your team with the strategies needed to overcome the current challenges and ensure a high quality, regulatory-compliant ADC product. Join 80+ senior analytical scientists, CMC leaders, and quality experts from leading organizations for three days of unparalleled insight and connection in Boston.The agenda has been created to help you decipher complex heterogeneity by exploring advanced strategies to move beyond average DAR and control full drug load distribution. It also addresses how to navigate novel degradation pathways and impurities arising from next-generation linkers and payloads.
You will gain practical guidance on designing biologically relevant bioassays for bispecific and dual-payload ADCs. The program also focuses on overcoming critical hurdles in transferring complex cell-based and analytical methods to CDMOs and QC laboratories, while navigating the regulatory landscape to construct compelling CMC narratives.
With 22+ expert-led case studies from analytical scientists and senior decision makers at AbbVie, Pfizer, AstraZeneca, Merck, and more, alongside 3 dedicated pre-conference workshops, you will gain the technical depth needed to optimize physicochemical, potency, and impurity analytical methods. This will enable effecting DAR assessment and support robust regulatory submissions for your ADC products.
Noteable Speakers:
Francis Poulin, Head of Analytical Development, Takeda Pharmaceutical
Melvin Flores, Senior Director of QC Analyitcal & Microbiology, Sutro Biopharma
John Valliere-Douglass, Senior Director - Analytical Scienes, Pfizer
Adrienne Wildt, Associate Director of Bioanalytical CMC, Abbvie
Susan Clardy, Director & Head of Analytical Development, Pyxis Oncology
Stacey Cummins-Bitz, Director of Analytical Scienes, Eli Lilly & Co
Amanda Ampey, Associate Director, AstraZeneca
Anita Liu, Associate Principal Scientist, Merck & Co
Yiyuan Ding, Senior Principal Scientist, Bristol Myers Squibb
What To Expect:
3 Days of Unmatched Technical Content
22+ Analytical Expert Speakers
12+ Hours of In-Person Netowkring
6+ Hours of Workshop Deep Dives
19 New Speakers
4 Panel Discussions
16 Companies Speaking
The Only Event for Tackling the Unique Analytical Complexities of ADC Development
